MIMEDX joins the RegenMed Hub

image: EPIFIX is a dehydrated human amniotic/chorionic membrane allograft used in wound healing.
see After

1 credit

WINSTON-SALEM, NC, September 12, 2022 – MIMEDX is the latest addition to the RegeneratOR Innovation Accelerator, located in the Regenerative Medicine Center (RegenMed Hub), a rapidly growing regenerative medicine ecosystem based in the neighborhood innovation of Winston-Salem.

MIMEDX is a placental biologics company and a pioneer in placental tissue engineering. Company has distributed over two million tissue allografts to date, primarily to meet the needs of patients with acute and chronic non-healing wounds, and is also advancing a promising pipeline of late-stage biologics aimed at reducing pain and improve function in patients with degenerative musculoskeletal conditions. MIMEDX will use the RegenMed Hub and its resources to advance science related to the application of placental technologies in multiple areas of wound care and regenerative medicine, with the goal of developing new products and optimizing treatment processes. manufacturing to advance the delivery of safe, innovative and evidence-based technologies to patients in a cost-effective manner.

Robert B. Stein, MD, Ph.D., President of MIMEDX, Regenerative Medicine and Biologics Innovation, said, “As a growing company within the Innovation Accelerator, the research, development teams and manufacturing MIMEDX can collaboratively advance the process efficiencies, biomanufacturing techniques, and advanced technologies needed to drive innovation in regenerative medicine, particularly in the area of ​​placental biologics. This opportunity strengthens our ability to create and engineer products that address the unmet clinical needs of patients and providers, and to advance the next generation of therapies for a wide range of disease states.

The RegenMed Hub is the destination for regenerative medicine and is powered by the Wake Forest Institute for Regenerative Medicine (WFIRM), Innovation Quarter and the RegenMed Development Organization (ReMDO). The RegendMed Hub offers companies, like MIMEDX, access to unparalleled resources to advance regenerative medicine products and manufacturing.

To officially join the RegenMed Hub, MIMEDX has secured a space within the Innovation Accelerator, a program that supports innovation from research to commercialization for start-ups, growing companies and established companies developing technologies emerging in regenerative medicine. Physical presence in the ecosystem provides unprecedented access to strategic partners, in addition to state-of-the-art bioproduction equipment, cutting-edge technologies, industry expertise, talent, a training program, and assets. other resources.

“We look forward to supporting MIMEDX with access to our testbed, which truly offers canned manufacturing solutions to optimize any manufacturing process with state-of-the-art equipment, technology and resources,” said Anthony. . Atala, MD, director of WFIRM.

Joshua Hunsberger, PhD, Chief Technology Officer of ReMDO, credits MIMEDX with his confidence in vision. “We believe this region has a lot to offer to help these companies succeed, and at the same time we can advance the field of regenerative medicine nationwide.”

Gary Green, EdD, COO of ReMDO, added, “Addressing manufacturing process optimization for companies in this space is the most critical need to enable these technologies to become mainstream, affordable and become the next standard of care.


MIMEDX is a transformational placental biologics company, which develops and distributes placental tissue allografts with patented and proprietary processes for multiple healthcare sectors. As a pioneer in placental tissue engineering, we have both commercial activity, focused on the needs of patients with acute and chronic non-healing wounds, and a promising late-stage pipeline aimed at reducing pain and improving function of patients with degenerative musculoskeletal disorders. conditions. We derive our products from human placental tissues and process these tissues using our proprietary methods, including the PURION® process. We use current good tissue practices, current good manufacturing practices and terminal sterilization to produce our allografts. MIMEDX has supplied over two million allografts, through direct and consignment shipments. For more information, please visit www.mimedx.com.



Jack Howard

Investor Relations


[email protected]


Hilary Dixon

Corporate and strategic communications


[email protected]

About the Wake Forest Institute for Regenerative Medicine

The Wake Forest Institute for Regenerative Medicine is recognized as an international leader in translating scientific discoveries into clinical therapies, with many world firsts, including the development and implantation of the first modified organ in a patient. More than 400 people at the Institute, the largest in the world, work on more than 40 different tissues and organs. A number of basic principles of tissue engineering and regenerative medicine were first developed at the Institute. WFIRM researchers have successfully designed replacement tissues and organs in all four categories – flat structures, tubular tissues, hollow organs and solid organs – and 15 different applications of cell/tissue therapy technologies, such as skin, tissue Urethra, cartilage, bladders, muscles, kidneys, and vaginal organs have been used successfully in human patients. The Institute, part of the Wake Forest School of Medicine, is located in the Innovation District in downtown Winston-Salem, North Carolina, and is driven by the urgent needs of patients. The Institute is making a global difference in regenerative medicine through collaborations with more than 400 entities and institutions around the world, through its government, academic and industrial partnerships, its start-ups and through major initiatives in the technologies of advanced, such as tissue engineering, cell therapies. , diagnostics, drug discovery, biomanufacturing, nanotechnology, gene editing and 3D printing.


Bonnie Davis, [email protected]; 336-713-1597

About the RegenMed Development Organization

The mission of the RegenMed Development Organization (ReMDO) is to accelerate the discovery and translation of regenerative medicine therapies. ReMDO is a 501(c)3 nonprofit organization that operates a clinical translation initiative that includes thought leaders, representatives from major US research centers, government officials, and businesses of all sizes. ReMDO conducts research to reduce the risks of technologies and accelerate the translation of regenerative medicine into clinical practice and the global market. ReMDO operates the world’s first and only professional organization dedicated solely to advancing the field of regenerative medicine, the Regenerative Medicine Manufacturing Society (RMMS) and the Regenerative Medicine Manufacturing Innovation Consortium (RegMIC), which operates a public-private partnership industrial and academic members. focused on scaling up technologies.